Patent · US Active

Bruton's tyrosine kinase inhibitors for hematopoietic mobilization

US9522917B2 · kind B2 · utility

2Cited by

0References

22Claims

0Family size

Assignee

Acerta Pharma B.V. · NL

Inventors

Raquel Izumi · Redwood City, US
Francisco Casas Salva · Sant Boi de Llobregat, ES
Ahmed Hamdy · Santa Cruz, US

Key dates

Filing date	Apr 11, 2013
Grant date	Dec 20, 2016
Priority date	—
Expiry date	Apr 11, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N5/0647
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods to improve hematopoiesis and increase white blood cell counts in subjects and patients using pyrimidine-based inhibitors of Bruton's tyrosine kinase (Btk) are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.